Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 458
- Registration Number
- NCT04530344
- Locations
- 🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 112
- Registration Number
- NCT04509700
- Locations
- 🇺🇸
Uab Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Rochester, Phoenix, Arizona, United States
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 209
- Registration Number
- NCT04476043
- Locations
- 🇺🇸
Investigative Site 018, Bellaire, Texas, United States
🇩🇪Investigative Site 403, Berlin, Germany
🇩🇪Investigative Site 401, Bochum, Germany
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 308
- Registration Number
- NCT04472429
- Locations
- 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇫🇷Chu Besancon Hospital Jean Minjoz, Besançon, France
🇺🇸Texas Oncology-Wichita Falls Texoma Cancer Center, Wichita Falls, Texas, United States
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT04463771
- Locations
- 🇺🇸
Advent Health Medical Group-Orlando 2501, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States
🇺🇸Alaska Womens Cancer Care Akwcc, Anchorage, Alaska, United States
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT04455841
- Locations
- 🇺🇸
Start Midwest, Grand Rapids, Michigan, United States
🇺🇸Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 211
- Registration Number
- NCT04377620
- Locations
- 🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States
🇺🇸Northshore University Health System, Chicago, Illinois, United States
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT04370704
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
- Conditions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04355793
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm Overlap SyndromeMyelodysplastic SyndromeMyeloproliferative NeoplasmRelapsed or Refractory Primary MyelofibrosisSecondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)ET (Essential Thrombocythemia)Myelofibrosis
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 231
- Registration Number
- NCT04279847
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu), Hangzhou, China
🇺🇸University of Alabama At Birmingham, Birmingham, Alabama, United States